DOCSLIB.ORG

A Aaas. See Abdominal Aortic Aneurysms Aads. See Adjuvant

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Aaas. See Abdominal Aortic Aneurysms Aads. See Adjuvant Index A Acetylsalicylic acid (ASA) treatment, cost-effectiveness of, AAAs. See Abdominal aortic coronary artery spasm, 957 2773, 2775 aneurysms MI, 938 Acute myocardial infarction (AMI), 21. AADs. See Adjuvant antiarrhythmic non-STEMI, 957 See also Non-ST elevation drugs stable angina, 922 acute myocardial infarction; Abciximab, 946, 950, 954 unstable angina, 954, 957 ST elevation acute myocardial AMI, 1024 ACHEIVETM stent, 1037 infarction adjunctive treatment with, 1023 Acquired immunodeficiency syndrome aging and, 2446 CAD, unstable, 1010 (AIDS) anterior wall KD, 986 antiviral therapies for, metabolic V4R value and, 65 non-STEMI, 957, 958 complications of, 2378 occlusions and, 62–64 STEMI, 968 treatment for, 2380 bundle branch block in, 1993–1994, transfusion/blood conservation, 2509 cardiac involvement, prevalence of at 1995 unstable angina, 957 autopsy, 2371–2372 treatment of, 1994 Abdominal aortic aneurysms (AAAs), cardiomyopathy in, 2376–2377 clinical recognition 1644–1648 alternative explanations for, auscultation, 681–683 background and history, 1771 2378–2379 ECG diagnosis, 683 clinical recognition, 1645, 1646–1647 cytokines as possible cause of, inspection and palpation, 679–681 endovascular procedures for 2378 myocardial scintigraphy, 686–687 treatment of drug-induced, 2379 myocardial stunning and patient selection, 1773–1774 myocardial cell injury and, 2378 hibernation, 683 stent grafts, design characteristics cardiovascular involvement in, serum enzyme and cardiac of, 1771–1773 2371–2381 intracellular substance natural history, 1644 PHT and, 2380–2381 changes in, 683–686 surgical repair, 1645–1648 DCM and, 1241–1242 complications of, echocardiography Abdominal disorders, PTE and, 2188 echocardiography and prevalence of and, 815–819 Ablation. See also specific ablations cardiovascular abnormalities coronary heart disease and, 677–691 AF, 1973–1974 in, 2372–2374 differential diagnosis, 687 SND, 1937 health care workers and, 2381 echocardiographic assessment of, ABT-578, DES, 1034 heart neoplasms and, 2272 813–814 ACAD. See Acyl-coenzyme A Acromegaly extent, echocardiography and, 815 dehydrogenase clinical manifestations, 2296–2297 glycoprotein IIb/IIIa inhibitor ACC/AHA. See American College of diagnosis, 2297 adjunctive treatment with, Cardiology/American Heart hypertension and, 1845–1846 1022–1034 Association pathophysiology, 2296 infarct extension and, 691 ACC/AHA/ESC. See American College treatment, 2297–2298 infarct size, estimation of, 687–688 of Cardiology/American Heart ACS. See Acute coronary syndrome location, echocardiography and, Association/European Society Actin, cardiac contraction and, 1192 814–815 of Cardiology Actinomyces infection, myocarditis non-anterior wall, 64 Accelerated idioventricular rhythm and, 1329 pathology, 597–600 (AIVR), 69 Actinomycin D, DCM and, 1240 PCI, 1021–1027 Acebutolol, SCD, 2061 Acute coronary syndrome (ACS), angioplasty, facilitated and, 1026 ACE inhibitors. See Angiotensin- 1089–1090 embolic protection and, 1024 converting enzyme inhibitors angiographic findings in, 783–787 no reflow and, 1025 Acetaminophen pathologic angiographic correlates rescue/salvage, 1024, 1026 pregnancy/lactation, 2475 and, 784 without surgical standby, 1026 STEMI, 973 culprit lesions responsible for, treatment, timing of, 1021–1023 Acetylcholine, coronary vasospasm, pathologic features of, 623 physical examination/bedside 789 DES, 1037–1038 findings, 678–679 Acetylcysteine, percutaneous coronary ECG, 60–69 progenitor cell therapy for, 1735 revascularization, 1089 exercise testing after, to risk stratify prognosis, 688–691 N-Acetylcysteine, radiographic contrast in emergency department, 738 echocardiography and, 821–823 material, 761 statins and, 1012–1013 remodeling of LV and, 691 2839 2840 index Acute myocardial infarction (AMI) diabetes mellitus, 2307 AIDS. See Acquired immunodeficiency (cont.) HCM, 1275 syndrome reperfusion therapy for, 1021 heart disease, carcinoid, 1305 AIVR. See Accelerated idioventricular SCD underlying disease and, 2046 heart failure, delaying progression of rhythm stent implantation, 1023, 1024 and, 1402–1404 Ajmaline, BS, 2054, 2588 thrombectomy, 1026–1027 hyperthyroidism, 2313 Albuterol, COPD, 2257 ventricular function, evaluation and, LQTS, 2033 Alcohol 688 SCD, 2045 abuse, heart and, 2361–2363 Acute rheumatic fever (ARF), 431 syncope, 2022, 2031 arrhythmias, cardiac related to, 2362 Acyclovir β-Adrenergic receptor-blocking agents atherosclerosis and effects of, amyloidosis, 1295 antiarrhythmic drugs and, 2086 2362–2363 nephrotoxicity, 1428 hypertrophy, cardiac, 1185 cardiac dysfunction and, 2361–2362 Acyl-coenzyme A dehydrogenase β-Adrenergic receptors cardiomyopathy, 2361 (ACAD), 2399 antagonists, cardiac hypertrophy, DCM and, 1237–1238 Adenosine, 143–144, 149, 2093–2095 1185 treatment, 2362 adverse effects, 2093–2095 hypertension, 1856 circulation and effects of, 2361 antiarrhythmic drugs and, 2086 inhibitors, DCM and, 1241 direct toxic effects, 2361–2362 dobutamine stress myocardial α-Adrenoceptor blockers, autonomic history, 2362 perfusion imaging and, disorders and, 1900 hypertension and, 1835, 1854 842–843 β-Adrenoceptor blockers myocardium and effects of, 2361 pharmacokinetics, 2093 hypotension, postural and, 1903 nutritional/vitamin deficiencies, pharmacology, 2093 sinus rhythm, 1967 2362 SND, 1934 SND, 1934 palpitations and, 24 STEMI, 973 extrinsic and, 1927 toxic additives, 2362 stress echocardiography, 825 Adrenomedullin, cardiovascular Alcohol septal ablation, SVT, 2090 regulation and, 1529 echocardiographic guidance of use, 2093 β2-Adrenoreceptor agonists, HCM with, 1370 Adenosine diphosphate radiographic contrast material, Aldosterone stable angina, 919 761 agonists, delaying progression of STEMI, 968 Adriamycin. See Doxorubicin heart failure and, 1406–1407 Adenosine thallium, silent myocardial ADT. See Adenosine triphosphate antagonists, SCD, 2063 ischemia, 708 Adult bone-marrow-derived stem cells, blockade Adenosine triphosphate (ADT) 2748 diastolic heart failure, 1212 cardiac contractile proteins and, Adult growth hormone deficiency, STEMI, 974 1192 2296 heart failure syncope testing with, 2031 AECG. See Ambulatory ECG cost-effectiveness of, 2781 Adhesion molecules, vulnerable plaque monitoring progression of, delaying and, 1407 detection and, 647–648 AF. See Atrial fibrillation Aldosteronism, primary, 1844–1845, Adipose tissue Aggrenox. See Aspirin-dipyridamole 1848 cardiovascular impact and increased Aging Allograft rejection, transplantation mass of, 2694–2696 arrhythmias, 2447–2448 and, 1421 circulation, 2694–2695 arterial compliance abnormalities Allopurinol Adjuvant antiarrhythmic drugs and, 1819–1820 gout, 1430 (AADs), direct current cardiac effects of, 2175–2477 hypersensitivity angiitis, 2344 cardioversion and, 1965 cardiovascular, 2439–2448 Alprostadil, 2792 Adrenal insufficiency, 2298 β-adrenergic modulation of, Amantadine Adrenal medulla, diseases of, 2442–2443 COPD, 2258 2301–2302 cardiac structure/function at rest SCD, 2045 α-Adrenergic agonists, coarctation of and, 2441 Ambulatory ECG (AECG) monitoring aorta, 1627 changes with, 2439–2443 limitations, 703–704 β-Adrenergic agonists, COPD, clinical medicine and, 2444–2445 silent ischemia, 703–704 2256–2257 exercise and, 2441–2442 exercise stress testing and, 704 β-Adrenergic antagonists key points for, 2439 myocardial perfusion imaging and, aortic dissection, 1641, 1642 vascular structure/function, 704–705 stable angina, 913–915 2439–2441 prognosis, 706–707 β-Adrenergic blockers CHF and, 2448 Amebiasis, PTE and, 2186 arrhythmias, primary cardiac, 2032 hypertension and, 2446–2447 American College of Cardiology/ cardiovascular performance, aging ischemic heart disease, 2445–2446 American Heart Association and, 2442–2443 AMI and, 2446 (ACC/AHA) cocaine-induced cardiovascular SCD risk factors and, 2042 arrhythmias, genetic basis for complication, 2360 AHA. See American Heart Association cardiac guidelines, 2592 index 2841 classifications, 742 SCD, 2058, 2063–2064, 2065, Anemia, 2409–2412 heart failure, advanced guidelines by, 2070–2071 heart failure and, 1386, 1411 1461 sinus rhythm, 1967–1968 hemolytic, 2411–2412 non-STEMI management guidelines, SVT, 2090 sickle cell, 2410 1013–1015 therapy, managing, 2090 thalassemia, 2410 pacing guidelines, 2134–2135 use, 2095 treatment TIA management guidelines, 1918 Amiodarone v. Implantable heart function and, 2828–2829 unstable angina management Cardioverter Defibrillator kidney function and, 2828–2829 guidelines, 1013–1015 (AMIOVIRT), 2069–2070 Anesthesia American College of Cardiology/ AMIOVERT. See Amiodarone v. agents, 2503–2505 American Heart Association/ Implantable Cardioverter airway devices, 2503 European Society of Defibrillator aortic insufficiency surgery, 2508 Cardiology (ACC/AHA/ESC), Amitriptyline, extrinsic SND and, beating heart surgery, 2509 2592 1927 CAD patient American Heart Association (AHA), Amlodipine noncardiac surgery and, 2495 1918. See also American antiarrhythmic effects of, 2100 surgery and, 2508 College of Cardiology/ DCM, 1251 cardiopulmonary bypass, 2510 American Heart Association heart failure, delaying progression of cardiovascular operation, 2501–2511 American trypanosomiasis, and, 1405–1406 changes during, and positive myocarditis and, 1330–1331 myocarditis, viral, 1320 pressure ventilation, AMI. See Acute myocardial silent myocardial ischemia, 707 2516–2517 infarction Amoxicillin, COPD, 2258 critical care unit transfer and, Amiloride, hypertension, 1856 Amphetamines 2511 Amino acids as cardiac metabolism abuse, 2363 history
Load more

Recommended publications
  • Eptifibatide Is Noninferior to Abciximab: Implications for Clinical Practice
    RESEARCH HIGHLIGHTS ANTIPLATELET THERAPY Eptifibatide is noninferior to abciximab: implications for clinical practice he glycoprotein IIb/IIIa (GPIIb/ randomized, open, parallel-group January 2004 and December 2007, IIIa) inhibitors eptifibatide and comparison of eptifibatide and abciximab and eptifibatide was used in 2,355 Tabciximab have comparable efficacy in 427 patients presenting within 12 h such procedures over this time frame. and safety in patients with ST-segment of STEMI onset and who underwent During the 1-year follow-up period, elevation myocardial infarction (STEMI) primary PCI. Enrolled patients were from no significant difference was reported undergoing primary percutaneous 22 centers in France and Germany. The for the incidence of death (8.0% and coronary intervention (PCI). These two study drugs were administered in 7.6%), myocardial infarction (9.0% and findings, from a randomized trial and a combination with background therapy 8.4%), or bleeding (2.7% and 3.2%) registry study, are reported in two papers comprising clopidogrel, aspirin, and between abciximab and eptifibatide, published in the Journal of the American heparin or enoxaparin. This study used respectively. Multivariable analysis College of Cardiology (JACC). the surrogate primary end point of showed that eptifibatide was noninferior Platelet aggregation and thrombus complete electrocardiographic ST-segment to abciximab for the prevention of death formation can be inhibited by blocking resolution (STR) 60 min after completion or myocardial infarction (odds ratio 0.94, the GPIIb/IIIa receptor on the platelet of PCI. 95% CI 0.82–1.09). membrane, thereby preventing the binding In the intention-to-treat analysis, These findings “fuel an already much of fibrinogen.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,697,347 B2
    USOO8697347B2 (12) UnitedO States Patent (10) Patent No.: US 8,697,347 B2 Sehgal (45) Date of Patent: *Apr. 15, 2014 (54) COMPOSITION FOR PRESERVING OTHER PUBLICATIONS PLATELETS AND METHOD OF USING THE SAME Furman et al., “GPllb-Illa Antagonist-induced Reduction in Platelet Surface Factor ViVa Binding and Phosphatidylserine Expression in (75) Inventor: Lakshman R. Sehgal, Monarch Beach, Whole Blood”. Thromb. Haemost. 84: 492-8 (2000).* CA (US) Uzan, 'Antithrombotic agents'. Chapter 12, Emerging Drugs 3 : 189-208 (1998).* (73) Assignee: Biovec Transfusion, LLC, Chicago, IL Agranenko et al., “Preparing platelet concentrates from banked blood (US) stored for 1-5 days by using tetracycline antibiotics”. Folia Haematologica 110 (6): 879-86 (1982), abstract only.* ( c ) Notice: Subject to any disclaimer, the term of this International Search Report (Application No. PCT/US2003/038.125, patent is extended or adjusted under 35 filed Dec. 2, 2003). U.S.C. 154(b) by 300 days. Abendschein. D.R., et al., “Effects of ZK-807834, a Novel Inhibitor of Factor Xa, on Arterial and Venous Thrombosis in Rabbits', J. This patent is Subject to a terminal dis- Cardiovasc. Pharmacol., vol. 35. No. 5, pp. 796-805, retrieved Oct. claimer. 11, 2006, <http:\\gateway.ut.ovid.com.gwllovidweb.cgi>, May 2000. (21) Appl. No.: 13/098,128 Ostrem, JA, et al., “Discovery of a Novel, Potent, and Specific Family of Factor Xa Inhibitors via Combinatorial Chemistry, Biochemistry, (22) Filed: Apr. 29, 2011 vol. 37, No. 4, pp. 1053-1059, 1998. Hirsh, J. et al., “New antithrombotic agents'. The Lancet, vol. 353, (65) Prior Publication Data pp.
    [Show full text]
  • Deliverable 5.A Interim Report on the Study Results APPENDIX 2
    Deliverable 5.a Interim report on the study results APPENDIX 2: Algorithms used to identify study variables for service contract EMA/2011/38/CN ‐ PIOGLITAZONE November 28th 2012 D5.a Interim report on the study results (Appendix 2) for Service Contract EMA/2011/38/CN PIOGLITAZONE Author(s): Vera Ehrenstein (AUH‐AS) APPENDIX 2. ALGORITHMS USED TO IDENTIFY STUDY VARIABLES Algorithms for AU Database DISEASE/CONDITION ICD-8 CODE (1977-1993) ICD-10 CODE (1994-) Diabetes type 2 250.00; 250.06; 250.07; 250.09 E11.0; E11.1; E11.9 Cancer of bladder 188 C67 Haematuria N/A R31 Haematuria, unspecified B18, K70.0–K70.3, K70.9, K71, K73, Mild hepatic impairment 571, 573.01, 573.04 K74, K76.0 Moderate to severe hepatic 070.00, 070.02, 070.04, 070.06, B15.0, B16.0, B16.2, B19.0, K70.4, impairment 070.08, 573.00, 456.00–456.09 K72, K76.6, I85 Acute myocardial infarction 410 I21-I23 Acute coronary syndrome 410, 413 I20-I24 Ischemic heart disease 410-414 I20-I25 427.09, 427.10, 427.11, 427.19, Congestive heart failure I50, I11.0, I13.0,I13.2 428.99, 782.49; Acute renal failure N/A N17 Diabetic coma N/A E10.0, E11.0, E12.0,E13.0, E14.0 Diabetic acidosis N/A E10.1, E11.1, E12.1,E13.1, E14.1 F10.1-F10.9, G31.2, G62.1, G72.1, Alcoholism 291, 303, 577.10, 571.09, 571.10 I42.6, K29.2, K86.0, Z72.1 Obesity 277.99 E65-E66 D5.a Interim report on the study results (Appendix 2) for Service Contract EMA/2011/38/CN PIOGLITAZONE Author(s): Vera Ehrenstein (AUH‐AS) Algorithms for defining acute events in Denmark, ICD-10 code Event ICD-10 code I21.x, I23.x http://apps.who.int/classifications/icd10/browse/2010/en#/I21
    [Show full text]
  • Antithrombotic Treatment After Stroke Due to Intracerebral Haemorrhage (Review)
    Cochrane Database of Systematic Reviews Antithrombotic treatment after stroke due to intracerebral haemorrhage (Review) Perry LA, Berge E, Bowditch J, Forfang E, Rønning OM, Hankey GJ, Villanueva E, Al-Shahi Salman R Perry LA, Berge E, Bowditch J, Forfang E, Rønning OM, Hankey GJ, Villanueva E, Al-Shahi Salman R. Antithrombotic treatment after stroke due to intracerebral haemorrhage. Cochrane Database of Systematic Reviews 2017, Issue 5. Art. No.: CD012144. DOI: 10.1002/14651858.CD012144.pub2. www.cochranelibrary.com Antithrombotic treatment after stroke due to intracerebral haemorrhage (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 5 OBJECTIVES ..................................... 5 METHODS ...................................... 6 RESULTS....................................... 8 Figure1. ..................................... 9 Figure2. ..................................... 11 Figure3. ..................................... 12 DISCUSSION ..................................... 14 AUTHORS’CONCLUSIONS . 15 ACKNOWLEDGEMENTS . 15 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 18 DATAANDANALYSES. 31 Analysis 1.2. Comparison 1 Short-term antithrombotic treatment, Outcome 2 Death. 31 Analysis 1.6. Comparison 1 Short-term antithrombotic
    [Show full text]
  • AHS Provincial High-Alert Medication List
    Provincial High-alert Medication List Classes/Categories of Medications Specific Medications adrenergic agonists: IV (e.g., epiNEPHrine, ePHEDrine, isoproterenol, magnesium sulfate injection PHENYLephrine, norepinephrine, doBUTamine, doPAMine, salbutamol) methotrexate: oral for non-oncologic adrenergic antagonists: IV (e.g., propranolol, metoPROLOL, labetalol, use esmolol) nitroprusside sodium for injection anesthetic agents: general, inhaled and IV (e.g., propofol, ketamine, sevoflurane, isoflurane, desflurane, etomidate) opium tincture antiarrhythmics: IV (e.g., lidocaine, amiodarone, procainamide, oxytocin: IV adenosine, bretylium, ibutilide) potassium chloride for injection: antithrombotic agents: concentrate anticoagulants (e.g., warfarin, acenocoumarol, tinzaparin, potassium phosphates injection enoxaparin, dalteparin, danaparoid, unfractionated heparin, sodium citrate) promethazine: IV factor Xa inhibitors (e.g., fondaparinux, rivaroxaban) vasopressin: IV or intraosseous direct thrombin inhibitors (e.g., apixaban, argatroban, bivalirudin, dabigatran) thrombolytics (e.g., alteplase, tenecteplase) glycoprotein IIb/IIIa inhibitors (e.g.,eptifibitide, tirofiban, abciximab) cardioplegic solutions chemotherapeutic agents: parenteral and oral dextrose: 20% or greater (hypertonic) dialysis solutions: peritoneal and hemodialysis The following medications are also epidural or intrathecal medications associated with higher risk and must inotropic medications: IV (e.g., digoxin, milrinone) comply with the segregated storage and labelling
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,518,244 B2 Cardin Et Al
    USOO651824.4B2 (12) United States Patent (10) Patent No.: US 6,518,244 B2 Cardin et al. (45) Date of Patent: Feb. 11, 2003 (54) COMBINATIONS OF HEPARIN COFACTOR OTHER PUBLICATIONS II AGONIST AND PLATELET IIB/IIIA Nicolini et al. Chem. Abst. 121:170,096 (1994).* ANTAGONIST, AND USES THEREOF Pavao et al., “A Unique Dermatan Sulfate-Like Glycosami noglycan from Ascidian,” J. Biol. Chem., (Dec. 29, 1995) (75) Inventors: Alan D. Cardin, Cincinnati, OH (US); 270(52):31027-31036. Cornelius L. Van Gorp, Springboro, Pouplard et al., “Antibodies to Platelet Factor 4-Heparin OH (US) After Cardiopulmonary Bypass in Patients Anticoagulated with Unfractionated Heparin or a Low Molecular Weight (73) Assignee: IntimaX Corporation, Cincinnati, OH Heparin:clinical Implications for Heparin-Induced Throm (US) bocytopenia.” Circulation (1999) 99:2539-2536. Prandoni et al., “Dermatan Sulfate: a Safe Approach to Notice: Subject to any disclaimer, the term of this Prevention of Postoperative Deep Vein Thrombosis,” Br. J. patent is extended or adjusted under 35 Surg. (1992) 79(6):505–509. U.S.C. 154(b) by 57 days. Adgey, “Bleeding Complications with New Antithrombotics Used in Ischemic Heart Disease,” Haemostasis (1996) 26(5):237-246. Agnelli et al., “A Randomized Double-Blind, Placebo-Con (21) Appl. No.: 09/802,775 trolled Trial of Dermatan Sulphate for Prevention of Deep (22) Filed: Mar. 9, 2001 Vein Thrombosis in Hip Fracture.” Thromb. Haemostas. (1992) 67:203-208. (65) Prior Publication Data Agnelli, “New Antithrombins and Nonheparin Glycosami noglycans in Clinical Development,” Vessels (1995) 1:9-16. US 2001/0036932 A1 Nov. 1, 2001 Ali et al., “Diffuse Alveolar Hemorrhage Following Admin istration of Tirofiban or Abciximab: a Nemesis of Platelet Related U.S.
    [Show full text]
  • Antithrombotic Agents in the Management of Sepsis
    Antithrombotic Agents in the Management of Sepsis !"#$ Loyola University Medical Center, Maywood, Illinois-60153, USA ABSTRACT Sepsis, a systemic inflammatory syndrome, is a response to infection and when associated with mul- tiple organ dysfunction is termed, severe sepsis. It remains a leading cause of mortality in the critically ill. The response to the invading bacteria may be considered as a balance between proinflammatory and antiinflammatory reaction. While an inadequate proinflammatory reaction and a strong antiinflammatory response could lead to overwhelming infection and death of the patient, a strong and uncontrolled pro- inflammatory response, manifested by the release of proinflammatory mediators may lead to microvas- cular thrombosis and multiple organ failure. Endotoxin triggers sepsis by releasing various mediators inc- luding tumor necrosis factor-alpha and interleukin-1(IL-1). These cytokines activate the complement and coagulation systems, release adhesion molecules, prostaglandins, leukotrienes, reactive oxygen speci- es and nitric oxide (NO). Other mediators involved in the sepsis syndrome include IL-1, IL-6 and IL-8; arachidonic acid metabolites; platelet activating factor (PAF); histamine; bradykinin; angiotensin; comp- lement components and vasoactive intestinal peptide. These proinflammatory responses are counterac- ted by IL-10. Most of the trials targeting the different mediators of proinflammatory response have failed due a lack of correct definition of sepsis. Understanding the exact pathophysiology of the disease will enable better treatment options. Targeting the coagulation system with various anticoagulant agents inc- luding antithrombin, activated protein C (APC), tissue factor pathway inhibitor (TFPI) is a rational appro- ach. Many clinical trials have been conducted to evaluate these agents in severe sepsis.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,835,407 B2 Mosher Et Al
    US008835407B2 (12) United States Patent (10) Patent No.: US 8,835,407 B2 Mosher et al. (45) Date of Patent: *Sep. 16, 2014 (54) PHARMACEUTICAL COMPOSITIONS 5,324,718 A 6/1994 Loftsson COMPRISING PRASUGREL AND 5,376,645 A 12, 1994 Stella et al. CYCLODEXTRIN DERVATIVES AND 3:3: A .22 seal. METHODS OF MAKING AND USING THE 5576,328 A 1 1/1996 Herbert et al. SAME 5,632,275 A 5/1997 Browne et al. 5,874,418 A 2f1999 Stella et al. (75) Inventors: Gerold L. Mosher, Kansas City, MO 357. A 1 A.28 t al (US), Stephen G. Michatha, Waltham, 6,071,514. A 6/2000 GrinnellCai Ca. et al. MA (US); Daniel J. Cushing, 6,133,248. A 10/2000 Stella Phoenixville, PA (US) 6,153,746 A 1 1/2000 Shah et al. 6,204.256 B1 3/2001 Shalaby et al. (73) Assignee: CyDex Pharmaceuticals, Inc., La Jolla, 6.248,729 B1 6/2001 Coniglio et al. CA (US) 6,294,192 B1 9/2001 Patel et al. 6,383,471 B1 5, 2002 Chen et al. (*) Notice: Subject to any disclaimer, the term of this 6,451,3396,429,210 B2B1 9/20028, 2002 B styletet alal. patent is extended or adjusted under 35 6,504,030 B1 1/2003 Bousquet et al. U.S.C. 154(b) by 0 days. 6,509.348 B1 1/2003 Ogletree 6,569.463 B2 5/2003 Patel et al. This patent is Subject to a terminal dis- 6,573.381 B1 6/2003 Bousquet et al.
    [Show full text]
  • Undergoing Elective Angioplasty in Patients with Stable Coronary Artery
    Downloaded from heart.bmjjournals.com on 17 October 2006 Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty K M Akkerhuis, M J B M van den Brand, C van der Zwaan, H O J Peels, H Suryapranata, L R van der Wieken, J Stibbe, J Hoffmann, T Baardman, J W Deckers and M L Simoons Heart 2001;85;444-450 doi:10.1136/heart.85.4.444 Updated information and services can be found at: http://heart.bmjjournals.com/cgi/content/full/85/4/444 These include: References This article cites 27 articles, 17 of which can be accessed free at: http://heart.bmjjournals.com/cgi/content/full/85/4/444#BIBL 1 online articles that cite this article can be accessed at: http://heart.bmjjournals.com/cgi/content/full/85/4/444#otherarticles Rapid responses You can respond to this article at: http://heart.bmjjournals.com/cgi/eletter-submit/85/4/444 Email alerting Receive free email alerts when new articles cite this article - sign up in the box at the service top right corner of the article Topic collections Articles on similar topics can be found in the following collections Drugs: cardiovascular system (857 articles) Ischemic heart disease (2078 articles) Notes To order reprints of this article go to: http://www.bmjjournals.com/cgi/reprintform To subscribe to Heart go to: http://www.bmjjournals.com/subscriptions/ Downloaded from heart.bmjjournals.com on 17 October 2006 444 Heart 2001;85:444–450 Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty K M Akkerhuis, MJBMvandenBrand, C van der Zwaan, HOJPeels, H Suryapranata, L R van der Wieken, J Stibbe, J HoVmann, T Baardman, J W Deckers, M L Simoons Abstract Objective—Lefradafiban is the orally active prodrug of fradafiban, a glycoprotein IIb/IIIa receptor antagonist.
    [Show full text]
  • The Efficacy and Safety of Combination Glycoprotein Iibiiia Inhibitors And
    Interventional Cardiology The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy–facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: A meta-analysis of randomized clinical trials Mohamad C.N. Sinno, MD, Sanjaya Khanal, MD, FACC, Mouaz H. Al-Mallah, MD, Muhammad Arida, MD, and W. Douglas Weaver, MD Detroit, MI Objective We reviewed the literature and performed a meta-analysis comparing the safety and efficacy of adjunctive use of reduced-dose thrombolytics and glycoprotein (Gp) IIbIIIa inhibitors to the sole use of Gp IIbIIIa inhibitors before percutaneous coronary intervention (PCI) in patients presenting with acute ST-segment elevation myocardial infarction (STEMI). Background Early reperfusion in STEMI is associated with improved outcomes. The use of reduced-dose thrombolytic and Gp IIbIIIa inhibitors combination before PCI in the setting of acute STEMI remains controversial. Methods We performed a literature search and identified randomized trials comparing the use of combination therapy–facilitated PCI versus PCI done with Gp IIbIIIa inhibitor alone. Included studies were reviewed to determine Thrombolysis in Myocardial Infarction (TIMI)-3 flow at baseline, major bleeding, 30-day mortality, TIMI-3 flow after PCI,and 30-day reinfarction. We performed a random-effect model meta-analysis. We quantified heterogeneity between studies with I2. A value N50% represents substantial heterogeneity. Results We identified 4 clinical trials randomizing 725 patients; 424 patients were pretreated with combination therapy before PCI, and 301 patients had Gp IIbIIIa inhibitor alone during PCI. Combination therapy–facilitated PCI was associated with a 2-fold increase in TIMI-3 flow upon arrival to the catheterization laboratory compared with the sole use of upstream Gp IIbIIIa inhibitors (192/390 patients [49%] versus 60/284 [21%]; relative risk [RR], 2.2; P b .00001).
    [Show full text]
  • Antiplatelet Therapy in Cardiovascular Disease M W H Behan, R F Storey
    155 Postgrad Med J: first published as 10.1136/pgmj.2003.007062 on 11 March 2004. Downloaded from CARDIOLOGY UPDATE Antiplatelet therapy in cardiovascular disease M W H Behan, R F Storey ............................................................................................................................... Postgrad Med J 2004;80:155–164. doi: 10.1136/pgmj.2003.007062 Platelet activation and aggregation are considered to be and collagen covered by a layer of connective tissue. Also present in the core are cholesterol- central to arterial thrombus formation. Antiplatelet therapy containing macrophages (foam cells), derived is therefore important for both the treatment and prevention from monocytes that have crossed the endothe- of cardiovascular disease. Aspirin, the most widely used lium from the arterial lumen. These cells produce large amounts of prothrombotic tissue factor antiplatelet agent, inhibits platelet cyclo-oxygenase and the together with several inflammatory cell media- conversion of arachidonic acid to the potent platelet tors such as tumour necrosis factor-a and various agonist thromboxane A but does not prevent platelet interleukins.3910 2 The process of thrombosis starts when the activation occurring via various signalling pathways that atherosclerotic plaque tears and exposes the are independent of thromboxane A2 release. Therefore a lipid-rich core to blood in the arterial lumen. number of other compounds have been developed to Platelet adherence to the exposed subendothe- lium and collagen results in platelet activation complement aspirin’s beneficial effect. These include the and the release and local accumulation of soluble thienopyridines (clopidogrel and ticlopidine), platelet agonists (thrombin, adenosine dipho- dipyridamole, and the a b (glycoprotein IIb/IIIa) receptor sphate (ADP), serotonin, and thromboxane A2). IIb 3 This in turn causes further platelet aggregation, inhibitors.
    [Show full text]
  • Neuraxial Access Or Peripheral Nerve Procedures)
    Management of Periprocedural Anticoagulation (Neuraxial Access or Peripheral Nerve Procedures) Below are guidelines to prevent spinal hematoma following Epidural/Intrathecal/Spinal procedures and perineural hematoma following peripheral nerve procedures. Procedures include epidural injec- tions/infusions, intrathecal injections/infusions/pumps, spinal injections, peripheral nerve catheters, and plexus infusions. Decisions to deviate from guideline recommendations given the specific clinical situation are the decision of the provider. See ‘Additional Comments’ section for more details. PRIOR to Neuraxial/ WHILE Neuraxial/Nerve AFTER Neuraxial/Nerve Comments Nerve Procedure Catheter in Place Procedure How long should I hold prior When can I restart to neuraxial procedure? (i.e. anticoagulants after neuraxial Can I give anticoagulants minimum time between the procedures? (i.e. minimum What additional information do I need to consider for the care of Anticoagulant concurrently with neuraxial, last dose of anticoagulant and time between catheter removal patients? peripheral nerve catheter, or spinal injection OR neuraxial/ or spinal/nerve injection and plexus placement? nerve placement) next anticoagulation dose) Low-Molecular Weight Heparin, Unfractionated Heparin, and Fondaparinux Maximum total heparin dose of 10,000 units per day (5000 SQ Q12 hrs) Unfractionated Heparin 5000 units Q 12 hrs – no time Heparin 5000 units SQ 8 hrs is NOT recommended with concurrent SQ Yes 2 hrs restrictions neuraxial catheter in place Prophylaxis Dosing For IV prophylactic dosing, use ‘treatment’ IV dosing recommendations. Unfractionated Heparin SQ: 8-10 hrs SQ/IV No 2 hrs See ‘Additional Comments’ IV: 4 hrs Treatment Dosing Enoxaparin (Lovenox), Caution in combination with other hemostasis-altering No (Note: May be used for Dalteparin (Fragmin) 12 hrs 4 hrs medications.
    [Show full text]